17.99
-0.58 (-3.11%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | CareDx, Inc. | Bullish | Bullish |
Stockmoo Score
|
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company’s commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (BTIG, 122.31%) | Buy |
| Median | 30.00 (66.73%) | |
| Low | 26.00 (Goldman Sachs, 44.50%) | Buy |
| Average | 31.50 (75.07%) | |
| Total | 3 Buy, 1 Sell | |
| Avg. Price @ Call | 28.24 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 27 Aug 2024 | 28.00 (55.62%) | Sell | 31.80 |
| BTIG | 19 Aug 2024 | 40.00 (122.31%) | Buy | 33.99 |
| Craig-Hallum | 01 Aug 2024 | 32.00 (77.85%) | Buy | 23.58 |
| Goldman Sachs | 01 Aug 2024 | 26.00 (44.50%) | Buy | 23.58 |
| 17 Jul 2024 | 16.00 (-11.08%) | Buy | 18.30 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 16 Aug 2024 | Announcement | CareDx Announces Transplant Community Secures Win Reaffirming Longstanding Medicare Coverage for AlloSure and AlloMap Testing |
| 31 Jul 2024 | Announcement | CareDx Reports Second Quarter 2024 Results and Increases Revenue Guidance |
| 16 Jul 2024 | Announcement | CareDx to Report Second Quarter 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |